New website coming soon
Copyright © 2020 Galen Limited.
Data Protection & Privacy Policy
Launch of innovative medical food provides a palatable new option for people diagnosed with rare metabolic disorder in the UK
Craigavon, N.I., 8 Jan 2020 – Galen, the privately owned global pharmaceutical sales and marketing company, today announced the
Gothenberg and Zug, 21st February 2019 – POA Pharma Scandinavia AB, a market-oriented Boutique Healthcare Company, working in close contact
Gothenburg and San Francisco, CA May 24, 2018:POA Pharma Scandinavia AB (“POA”), a market oriented Boutique Healthcare Company, working in
POA Pharma Scandinavia AB signs distribution agreement with Darou Darman Kian Co for marketing and sale of POA Pharma´s metabolic
POA Pharma Scandinavia AB expands its partnership with Metabol Med to include exept the IEM products also the Antisecretory Factor
POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands there existing Promotion & Distribution Agreements for EMSELEX®/ENABLEX® and
POA Pharma Scandinavia AB signs distribution agreement with Galen Limited for marketing and sale of POA Pharma´s metabolic product portfolio
MARS 2011 – MARS 2016. POA Pharma Scandinavia AB celebrating it's first five years! March 1, 2011 POA was
POA Pharma Scandinavia AB signs distribution agreement with FederalMed, Buenos Aires, Argentina for marketing and sale of POA Pharma´s products
POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands there existing Promotion & Distribution Agreements for EMSELEX®/ENABLEX® with
2015 The year that was: Continued success for POA Pharma and international breakthrough for our Metabolic range of products.
2015 The year that was: Continued success for POA Pharma and international breakthrough for our Metabolic range of products.
2015 The year that was: Continued success for POA Pharma and international breakthrough for our Metabolic range of products.
POA Pharma in an expansive phase: Increasing ownership in North American distributor, growing export globally (Photo TMS) POA Pharma
Antisecretory Factor (AF) is a protein secreted in plasma and tissue fluids in mammals. This 41-kDA protein provides protection against
A total of 550 ENT specialists from 52 countries had gathered in Rome the 17th-20th of October to participate in
About Akineton. Biperiden is a medium-parkinsonian of anticholinergic type. In the Nordics, the medicine exists under the name of Akineton.
POA Pharma Scandinavia AB signs distribution agreement with South African based Cape Medicine, regarding SPC Flakes® and Salovum® for South
Bakgrund TLV beslutade att Emselex skulle undantas från Läkemedelsförmånen fr.o.m. 1:e februari 2015. POA Pharma Scandinavia (bolaget) överklagade beslutet från